Zacks Research Issues Positive Outlook for JAZZ Earnings

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Research analysts at Zacks Research boosted their Q1 2027 earnings estimates for Jazz Pharmaceuticals in a research report issued to clients and investors on Monday, February 2nd. Zacks Research analyst Team now anticipates that the specialty pharmaceutical company will post earnings per share of $3.82 for the quarter, up from their prior forecast of $3.80. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share.

JAZZ has been the topic of several other reports. JPMorgan Chase & Co. reduced their price target on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a report on Monday, October 27th. Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Finally, Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Fourteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $205.67.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $166.84 on Tuesday. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The stock has a market cap of $10.14 billion, a PE ratio of -27.49, a PEG ratio of 0.90 and a beta of 0.26. Jazz Pharmaceuticals has a 12-month low of $95.49 and a 12-month high of $182.99. The business has a 50-day simple moving average of $168.58 and a two-hundred day simple moving average of $144.68.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 5,319 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $182.06, for a total value of $968,377.14. Following the transaction, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at $1,276,604.72. The trade was a 43.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Rick E. Winningham sold 5,500 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total value of $994,730.00. Following the sale, the director owned 8,893 shares in the company, valued at approximately $1,608,387.98. The trade was a 38.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 123,791 shares of company stock worth $21,991,850. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Cardinal Capital Management lifted its position in shares of Jazz Pharmaceuticals by 0.5% during the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after acquiring an additional 66 shares during the period. EverSource Wealth Advisors LLC increased its stake in Jazz Pharmaceuticals by 9.0% in the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 81 shares in the last quarter. Tectonic Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 1.5% during the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock valued at $742,000 after purchasing an additional 82 shares during the period. Teacher Retirement System of Texas raised its holdings in shares of Jazz Pharmaceuticals by 0.6% during the second quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock valued at $1,651,000 after purchasing an additional 90 shares during the period. Finally, Fairbanks Capital Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 0.4% during the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after purchasing an additional 94 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.